MERCURY LABORATORIES
|
|
BOM : 538964     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : NA |
Dec 05,2024 |
Price(EOD): ₹ 977.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 117.28 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MERCURY LABORATORIES | 2.3% | 4% | 17.6% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | 0.1% | 46.2% |
CIPLA | -2.3% | -5.4% | 24.4% |
DR REDDYS LABORATORIES | 3.2% | -2.2% | 5.8% |
ZYDUS LIFESCIENCES | 1.3% | -2.6% | 51.8% |
DIVIS LABORATORIES | -1.2% | 3.4% | 65% |
MANKIND PHARMA | 2.2% | -4.2% | 35.5% |
TORRENT PHARMACEUTICALS | 1.1% | 5.1% | 55.7% |
LUPIN | 3.7% | -2.9% | 62.1% |
FUNDAMENTAL ANALYSIS OF MERCURY LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MERCURY LABORATORIES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
29.4
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 3.99 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 2.31
P/B Calculated based on Book Value of Rs 50.84 Cr
[Latest Year - Mar2024 - Standalone Results ] 1.69
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
104% 79% 80% |
SHARE PRICE MOMENTUM OF MERCURY LABORATORIES
MERCURY LABORATORIES vs SENSEX
DEBT OF MERCURY LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.11 0.12 0.13 0.12 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MERCURY LABORATORIES
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MERCURY LABORATORIES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
9.1% -18.42% -29.02% 46.49% |
-20.04% -47.29% -67.8% -66.76% |
QtrlyTrend |
-4 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
MERCURY LABORATORIES related INDICES
You may also like the below Video Courses
FAQ about MERCURY LABORATORIES
Is MERCURY LABORATORIES good for long term investment?
As on Dec 05,2024, the Fundamentals of MERCURY LABORATORIES look Poor and hence it may not be good for long term investment ! See Financial Performance of MERCURY LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MERCURY LABORATORIES UnderValued or OverValued?
As on Dec 05,2024, MERCURY LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MERCURY LABORATORIES ?
As on Dec 05,2024, the Intrinsic Value of MERCURY LABORATORIES is Rs. 543.68 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 480.21
Fair Value [Median EV / Sales Model] : Rs. 546.68
Fair Value [Median Price / Sales Model] : Rs. 543.68
Estimated Median Fair Value of MERCURY LABORATORIES : Rs. 543.68
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.